Replies to post #170318 on Biotech Values

[biomaven0]

>throughput

I guess the underlying question here is what the physician burden is for the new treatments.

I suppose the limiting case would be one visit for consultation and genotyping, one visit for prescribing, and a 12 week "end-of-treatment" visit for confirmation of cure, likely with some nurse practitioner support added during the treatment period.

So how close to this limiting case do you think these regimens might come in practice?

I did have a pill-burden question on the Abbvie/Enta treatment. I saw someplace it will likely be one pill QD, plus 2 pills each BID. Is that correct? If so, compliance might be more of an issue than for GILD's offering.

Peter